T1	Age 2 13	44-year-old
T2	Personal_background 14 21	Chinese
T3	Sex 22 25	man
T4	History 33 60	7 pack-year smoking history
T5	Clinical_event 65 73	referred
E1	Clinical_event:T5 
T6	Nonbiological_location 77 104	Shanghai Pulmonary Hospital
R1	MODIFY Arg1:T6 Arg2:E1	
T7	Date 108 121	February 2013
E2	Date:T7 
T8	Sign_symptom 149 153	mass
E3	Sign_symptom:T8 
T9	Biological_structure 144 148	lung
T10	Biological_structure 128 143	left upper lobe
R2	MODIFY Arg1:T9 Arg2:E3	
R3	MODIFY Arg1:T10 Arg2:E3	
T11	Sign_symptom 193 203	metastases
E4	Sign_symptom:T11 
T12	Biological_structure 178 192	intrapulmonary
T13	Detailed_description 168 177	bilateral
T14	Detailed_description 159 167	multiple
R4	MODIFY Arg1:T12 Arg2:E4	
R5	MODIFY Arg1:T13 Arg2:E4	
R6	MODIFY Arg1:T14 Arg2:E4	
T15	Disease_disorder 210 226	pleural effusion
E5	Disease_disorder:T15 
T16	Detailed_description 205 209	left
R7	MODIFY Arg1:T16 Arg2:E5	
T17	Disease_disorder 246 261	lymphadenopathy
E6	Disease_disorder:T17 
T18	Lab_value 232 245	2R/4R/10L/11L
R8	MODIFY Arg1:T18 Arg2:E6	
T19	Diagnostic_procedure 277 285	cytology
E7	Diagnostic_procedure:T19 
T20	Biological_structure 263 276	Pleural fluid
R9	MODIFY Arg1:T20 Arg2:E7	
T21	Disease_disorder 295 309	adenocarcinoma
E8	Disease_disorder:T21 
T22	Diagnostic_procedure 314 363	Scorpion Amplification Refractory Mutation system
E9	Diagnostic_procedure:T22 
T23	Detailed_description 365 390	AmoyDx Co., Xiamen, China
R10	MODIFY Arg1:T23 Arg2:E9	
T24	Sign_symptom 414 455	epidermal growth factor receptor mutation
E10	Sign_symptom:T24 
A1	POLARITY E10 NEG
T25	Medication 470 482	chemotherapy
E11	Medication:T25 
T26	Medication 488 499	gemcitabine
E12	Medication:T26 
T27	Medication 504 513	cisplatin
E13	Medication:T27 
R11	SUB_PROCEDURE Arg1:E12 Arg2:E11	
R12	SUB_PROCEDURE Arg1:E13 Arg2:E11	
T28	Sign_symptom 550 558	symptoms
E14	Sign_symptom:T28 
A2	TREND E14 INC
T29	Disease_disorder 602 609	disease
E15	Disease_disorder:T29 
T30	Detailed_description 590 601	progressive
R13	MODIFY Arg1:T30 Arg2:E15	
T31	Clinical_event 613 641	second opinion was requested
E16	Clinical_event:T31 
T32	Nonbiological_location 651 673	University of Colorado
R14	MODIFY Arg1:T32 Arg2:E16	
T33	Diagnostic_procedure 707 713	biopsy
E17	Diagnostic_procedure:T33 
T34	Detailed_description 680 706	computed tomography–guided
R15	MODIFY Arg1:T34 Arg2:E17	
T35	Sign_symptom 737 743	lesion
E18	Sign_symptom:T35 
R16	MODIFY Arg1:E10 Arg2:E9	
T36	Biological_structure 721 736	left upper lobe
R17	MODIFY Arg1:T36 Arg2:E18	
R18	MODIFY Arg1:E18 Arg2:E17	
T37	Medication 836 846	pemetrexed
E19	Medication:T37 
T38	Medication 851 861	nedaplatin
E20	Medication:T38 
T39	Sign_symptom 899 918	shortness of breath
E21	Sign_symptom:T39 
A3	TREND E21 INC
T40	Diagnostic_procedure 973 978	scans
E22	Diagnostic_procedure:T40 
T41	Sign_symptom 946 965	further progression
E23	Sign_symptom:T41 
R19	MODIFY Arg1:E23 Arg2:E22	
T42	Diagnostic_procedure 1021 1027	biopsy
E24	Diagnostic_procedure:T42 
T43	Diagnostic_procedure 1081 1092	PCR testing
E25	Diagnostic_procedure:T43 
T44	Detailed_description 1062 1080	SNaPshot multiplex
R20	MODIFY Arg1:T44 Arg2:E25	
T45	Sign_symptom 1049 1058	mutations
E26	Sign_symptom:T45 
A4	POLARITY E26 NEG
R21	MODIFY Arg1:E26 Arg2:E25	
T46	Diagnostic_procedure 1188 1197	FISH test
E27	Diagnostic_procedure:T46 
T47	Detailed_description 1172 1187	ALK break-apart
R22	MODIFY Arg1:T47 Arg2:E27	
T48	Lab_value 1208 1233	atypical negative pattern
R23	MODIFY Arg1:T48 Arg2:E27	
T49	Diagnostic_procedure 1433 1450	diagnostic assays
E28	Diagnostic_procedure:T49 
T50	Medication 1738 1748	crizotinib
E29	Medication:T50 
T51	Dosage 1750 1768	250 mg twice daily
R24	MODIFY Arg1:T51 Arg2:E29	
T52	Date 1795 1803	May 2013
E30	Date:T52 
T53	Sign_symptom 1823 1846	symptomatic improvement
E31	Sign_symptom:T53 
T54	Medication 1927 1937	crizotinib
E32	Medication:T54 
T55	Sign_symptom 1958 1969	progression
E33	Sign_symptom:T55 
A5	POLARITY E33 NEG
T56	Date 1976 1990	September 2013
E34	Date:T56 
T57	Lab_value 1249 1309	68% of cells demonstrated single copies of the 5′ ALK signal
R25	MODIFY Arg1:T57 Arg2:E27	
T58	Lab_value 1314 1395	numerous cells with doublets of the 5′ ALK signal combined with one 3′ ALK signal
R26	MODIFY Arg1:T58 Arg2:E27	
T59	Lab_value 1464 1486	ALK protein expression
R27	MODIFY Arg1:T59 Arg2:E28	
T60	Diagnostic_procedure 1490 1493	IHC
E35	Diagnostic_procedure:T60 
#1	AnnotatorNotes E35	immunohistochemistry
T61	Detailed_description 1504 1517	D5F3 antibody
R28	MODIFY Arg1:T61 Arg2:E35	
R29	SUB_PROCEDURE Arg1:E35 Arg2:E28	
T62	Detailed_description 1519 1562	Cell Signaling Technology Inc., Danvers, MA
R30	MODIFY Arg1:T62 Arg2:T61	
T63	Lab_value 1595 1680	presence of an echinoderm microtubule-associated protein-like 4 (EML4)-ALK transcript
R31	MODIFY Arg1:T63 Arg2:E28	
T64	Diagnostic_procedure 1695 1701	RT-PCR
E36	Diagnostic_procedure:T64 
R32	SUB_PROCEDURE Arg1:E36 Arg2:E28	
*	OVERLAP E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11
R33	BEFORE Arg1:E11 Arg2:E14	
*	OVERLAP E14 E15
R34	BEFORE Arg1:E15 Arg2:E16	
*	OVERLAP E16 E17 E18 E19 E20
R35	BEFORE Arg1:E20 Arg2:E21	
*	OVERLAP E21 E23 E24 E26 E25 E27 E28
R36	BEFORE Arg1:E28 Arg2:E29	
*	OVERLAP E29 E30
R37	BEFORE Arg1:E30 Arg2:E31	
T65	Date 1863 1876	after 1 month
E37	Date:T65 
*	OVERLAP E31 E37
R38	BEFORE Arg1:E37 Arg2:E32	
*	OVERLAP E32 E33 E34
T66	Activity 45 52	smoking
E38	Activity:T66 
R39	BEFORE Arg1:E38 Arg2:E1	
